144 related articles for article (PubMed ID: 3258793)
21. Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity.
Kawakami Y; Klein TW; Newton C; Djeu JY; Specter S; Friedman H
Int J Immunopharmacol; 1988; 10(4):485-8. PubMed ID: 2844686
[TBL] [Abstract][Full Text] [Related]
22. Lysis of fresh murine mammary tumor cells by syngeneic natural killer cells and lymphokine-activated killer cells.
Ames IH; Gates CE; Garcia AM; John PA; Hennig AK; Tomar RH
Cancer Immunol Immunother; 1987; 25(3):161-8. PubMed ID: 3499983
[TBL] [Abstract][Full Text] [Related]
23. Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity.
Hsieh CT; Luo YH; Chien CS; Wu CH; Tseng PC; Chiou SH; Lee YC; Whang-Peng J; Chen YM
J Immunother; 2016 May; 39(4):153-9. PubMed ID: 27023059
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
Nishimura T; Burakoff SJ; Herrmann SH
J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
[TBL] [Abstract][Full Text] [Related]
25. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.
McVicar DW; Merchant RE; Merchant LH; Young HF
Cancer Immunol Immunother; 1989; 29(3):211-8. PubMed ID: 2499421
[TBL] [Abstract][Full Text] [Related]
27. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
28. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY
J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo suppression of interleukin-2-activated killer cell activity by chimeric proteins between interleukin-2 and Pseudomonas exotoxin.
Puri RK; FitzGerald D; Leland P; Kozak RW; Pastan I
Cell Immunol; 1992 Sep; 143(2):324-34. PubMed ID: 1511480
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
31. Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice.
Radzikowski C; Rygaard J; Budzynski W; Stenvang JP; Schou M; Vangsted A; Zeuthen J
APMIS; 1994 Jul; 102(7):481-8. PubMed ID: 7917216
[TBL] [Abstract][Full Text] [Related]
32. Asialo GM1 as an accessory molecule determining the function and reactivity of cytotoxic T lymphocytes.
Hargrove ME; Ting CC
Cell Immunol; 1988 Mar; 112(1):123-34. PubMed ID: 2449975
[TBL] [Abstract][Full Text] [Related]
33. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
34. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
[TBL] [Abstract][Full Text] [Related]
35. Lymphokine-activated killer (LAK) cells. I. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide.
Ballas ZK
J Immunol; 1986 Oct; 137(7):2380-4. PubMed ID: 3489763
[TBL] [Abstract][Full Text] [Related]
36. Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity.
Zanovello P; Cerundolo V; Bronte V; Giunta M; Panozzo M; Biasi G; Collavo D
Cell Immunol; 1989 Sep; 122(2):450-60. PubMed ID: 2788517
[TBL] [Abstract][Full Text] [Related]
37. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
38. Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG.
MacDougall JR; Croy BA; Chapeau C; Clark DA
Cell Immunol; 1990 Oct; 130(1):106-17. PubMed ID: 2144467
[TBL] [Abstract][Full Text] [Related]
39. Induction of lymphokine-activated killer cells from rat thymocytes using recombinant human interleukin-2.
Imaya H; Matsuura H; Kudo M; Nakazawa S
Cancer Immunol Immunother; 1988; 27(1):13-6. PubMed ID: 3260819
[TBL] [Abstract][Full Text] [Related]
40. Studies on cytotoxicity generated in human mixed lymphocyte culture. IV. Interleukin 2 alone or from mixed lymphocyte culture yields natural killer-like cytotoxic cells distinct from allospecific cytotoxic T lymphocytes.
Shau H; Gray JD; Golub SH
Cancer Immunol Immunother; 1988; 27(3):255-60. PubMed ID: 2972366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
